KRAS G12D MUTATION
Clinical trials for KRAS G12D MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS G12D MUTATION trials appear
Sign up with your email to follow new studies for KRAS G12D MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancer mutation in first human trial
Disease control Recruiting nowThis study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …
Matched conditions: KRAS G12D MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug targets Hard-to-Treat cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug, RNK08954, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to find a safe and effective dose and see if the drug can shrink tumors or slow their growth. About 152 adults who have already tried stan…
Matched conditions: KRAS G12D MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC